Posted by Michael Wonder on 13 Aug 2024
Insignis Therapeutics receives FDA fast track designation for IN-001 for anaphylaxis treatment
13 August 2024 - Convenient, needle-free, and simple to use liquid epinephrine sublingual spray.
Insignis Therapeutics is pleased to announce that the US FDA has granted fast track designation for its investigational drug, IN-001, a novel needle-free epinephrine delivery system utilising a sublingual spray in a disposable device.
